Telix Pharmaceuticals is trading 8.41% up at $11.53 after announcing its September 22, 2026 R&D Day in New York.
- The event will highlight therapeutic and precision-medicine pipeline programs, clinical developments, and strategic priorities.
- Company executives and external clinical experts will present.
- The announcement appears to have renewed investor interest, while broader gains in growth stocks following weak U.S. jobs data provided additional support.